Search

Search Constraints

You searched for: Author/Creator Govindan, R.

Search Results

1. 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer. (December 2022)

3. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015)

4. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). (September 2015)